WGS (GeneDx Holdings) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WGS GeneDx Holdings Corp WGS
65 GF Score
Price $90.32
GF Value $73.77
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GeneDx Holdings Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WGS
65GF Score
GeneDx Holdings Corp WGS
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GeneDx Holdings (WGS) Overvalued in 2026?

Based on GuruFocus' analysis, GeneDx Holdings stock appears to be overvalued. The current stock price of $90.32 is trading 22.4% above its estimated GF Value™ of $73.77. GuruFocus considers GeneDx Holdings to be Modestly Overvalued.

Key valuation signals for WGS:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: $73.77 vs. price of $90.32 (22.4% above fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the WGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneDx Holdings Business Description

Address 333 Ludlow Street, North Tower, 6th Floor, Stamford, CT, USA, 06902
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
65GF Score

Get the complete analysis for WGS

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.32
Price
$73.77
GF Value